Related Experiment Video

Updated: Jun 2, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable

Trine B Opstad1, Alf-Aage R Pettersen, Vibeke Bratseth

  • 1Department of Cardiology, Center for Clinical Heart Research, Oslo University Hospital, Oslo, Norway. trineoa@medisin.uio.no

Pathophysiology of Haemostasis and Thrombosis
|May 11, 2011
PubMed

Insights

Specific gene variations in tissue factor (TF) and TF pathway inhibitor (TFPI) influence thrombin generation in coronary heart disease patients. These genetic factors correlate with blood clotting markers, impacting cardiovascular risk.

Area of Science:

  • Cardiovascular Genetics
  • Hemostasis and Thrombosis

Background:

  • Coronary heart disease (CHD) involves complex hemostatic mechanisms.
  • Thrombin generation is a critical factor in thrombotic events.

Purpose of the Study:

  • To investigate the impact of tissue factor (TF) and TF pathway inhibitor (TFPI) gene polymorphisms on thrombin generation in stable CHD patients.
  • To correlate circulating TF and TFPI levels with thrombin generation parameters.

Main Methods:

  • Studied 1,001 patients with stable coronary heart disease.
  • Assessed in vivo thrombin generation using prothrombin fragment 1 and 2 levels.
  • Measured ex vivo thrombin generation potential with the calibrated automated thrombogram assay.
  • Analyzed TF and TFPI polymorphisms and circulating levels.

Main Results:

  • TF 5466 and TFPI -399 polymorphisms were linked to increased in vivo thrombin generation.
  • Specific TF genotypes (-1812 TT, -603 GG) correlated with reduced peak thrombin and activation rates.
  • TFPI -33 TC genotype was associated with prolonged lag time and time to peak thrombin generation.
  • Significant correlations were found between TFPI levels and both in vivo and ex vivo thrombin generation markers.

Conclusions:

  • Certain TF and TFPI polymorphisms significantly modulate thrombin generation in CHD.
  • Circulating TFPI levels are strongly associated with thrombin generation dynamics.
  • These findings highlight the role of genetic factors in thrombotic risk in coronary heart disease.

More Related Videos

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.